Sulfonamide inhibitors of matrix metalloproteinases
US6297247A · kind A · utility
4Cited by
11References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 22, 2000 |
| Grant date | Oct 2, 2001 |
| Priority date | — |
| Expiry date | Jun 22, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D401/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Sulfonamide compounds are described which are inhibitors of matrix metalloproteinases, particularly stromelysin-1 and gelatinase A (72 kD gelatinase). Also described are methods for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes using the compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.